Researchers compared the health outcomes of adult patients with moderate ulcerative colitis and early advanced therapy initiation with those who delayed their advanced treatment initiation.
Researchers compared the health outcomes of adult patients with moderate ulcerative colitis and early advanced therapy initiation with those who delayed their advanced treatment initiation.
The American Gastroenterological Association (AGA) released a set of guidelines that outlines the use of biomarkers to treat and monitor ulcerative colitis in patients.
The researchers sought to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe ulcerative colitis.
The researchers sought to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe ulcerative colitis.
Researchers conducted a systematic review and meta-analysis to evaluate the efficacy and safety of fecal microbiota transplantation as a treatment for ulcerative colitis.
Researchers conducted a systematic review and meta-analysis to evaluate the efficacy and safety of fecal microbiota transplantation as a treatment for ulcerative colitis.
The FDA has approved Humira (Adalimumab) for the treatment of moderately to severly active ulcerative colitis (UC) in pediatric patients aged 5 years or older.
The guideline authors developed more than 10 recommendations with the goal of promoting high-quality, high-value, evidence-based care for adult patients with moderate to severe ulcerative colitis.
